A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells

Two-in-One antibodies with dual action Fabs

(2013) Charles Eigenbrot et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Rapid optimization and prototyping for therapeutic antibody-like molecules

(2013) Lihui Xu et al.   mAbs

Antibodies to watch in 2013

(2013) Janice M Reichert   mAbs

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic Antibodies Against Cancer

(2012) Mark J. Adler et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

A recombinant triplebody with specificity for CD19 and HLA-DR mediates 
preferential binding to antigen double-positive cells by dual-targeting

(2012) Ingo Schubert et al.   mAbs

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

(2012) Christian Klein et al.   mAbs

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

(2011) Gabriele Schaefer et al.   CANCER CELL

Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design

(2011) Enrico L. DiGiammarino et al.   mAbs

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting

(2011) Ingo Schubert et al.   mAbs

Antibody-based therapeutics to watch in 2011

(2011) Janice M. Reichert   mAbs

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies

(2011) M. Muda et al.   PROTEIN ENGINEERING DESIGN & SELECTION

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature

(2010) Alexander K. Tsai et al.   JOURNAL OF NEURO-ONCOLOGY

Catumaxomab

(2010) Rolf Linke et al.   mAbs

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†

(2010) Jonathan H. Davis et al.   PROTEIN ENGINEERING DESIGN & SELECTION

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

(2009) S. Oh et al.   CLINICAL CANCER RESEARCH

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

(2008) E. Alici et al.   BLOOD

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

(2008) M K Robinson et al.   BRITISH JOURNAL OF CANCER

A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

(2008) Christian Kellner et al.   JOURNAL OF IMMUNOTHERAPY